The Dana-Farber Cancer Institute (DFCI) and Dana-Farber/Partners CancerCare (DF/PCC) proposes to use its membership in the Cancer and Leukemia Group B (CALGB) to support participation in therapeautic research and other clinical trials, both in the Institute and its affiliate institutions. The goals of this project will be the initiation and participation in Phase I, II and III cooperative clinical trials involving chemotherapy, surgery and radiation therapy. A major emphasis will be made in developing new therapeutic strategies both at DFCI, MGH and in pilot collaborative investigations with interested membersof CALGB. Dana-Farber investigators would continue to be actively involved in disease and modality committees of the CALGB. This project is designed to bring cooperative group trials to regional community hospitals affilaitedthrough the Dana-Farber Cancer Institute throughout New England.
With this application we propose to continue the collaborative DF/PCC efforts within CALGB and continue to make significant contributions to advancing oncology clinical research. We intend to continue the tradition set forth in Dana-Farber's previous grants of piloting studies in-house and subsequently bringing tested concepts to the Group for consideration as CALGB Phase II and III trials.
|Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7|
|Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38|
|Walker, Alison; Mrozek, Krzysztof; Kohlschmidt, Jessica et al. (2013) New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. Genes Chromosomes Cancer 52:385-401|
|Schwind, Sebastian; Edwards, Colin G; Nicolet, Deedra et al. (2013) inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood 121:385-91|
|Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47|
|Marks, Lawrence B; Cirrincione, Constance; Fitzgerald, Thomas J et al. (2010) Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys 76:1305-13|
|Kindler, Hedy Lee; Niedzwiecki, Donna; Hollis, Donna et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617-22|
|Adjei, Alex A; Mandrekar, Sumithra J; Dy, Grace K et al. (2010) Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 28:614-9|
|Graziano, Stephen L; Gu, Lin; Wang, Xiaofei et al. (2010) Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol 5:810-7|
|Partridge, Ann H; Archer, Laura; Kornblith, Alice B et al. (2010) Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 28:2418-22|
Showing the most recent 10 out of 145 publications